How effective is Brigatinib/Brigatinib in the treatment of lung cancer?

Brigatinib/Brigatinib (Brigatinib) is an oral anti-tumor drug mainly used to treat specific types of non-small cells Lung cancer (NSCLC), especially ALK fusion-positive NSCLC. By inhibiting the activity of ALK fusion protein, brigatinib can block abnormal signaling pathways and inhibit the growth and spread of tumor cells. In clinical trials, Brigatinib/Brigatinib showed significant anti-tumor activity and good efficacy. The following will discuss in detail the effect of brigatinib/brigatinib in the treatment of lung cancer based on clinical trial data.

1.Efficacy of first-line treatment:Brigatinib/Brigatinib has been evaluated in multiple clinical trials as a first-line treatment option. The most important of these is the ALTA-1L trial, which compared brigatinib and crizotinib in first-line treatment of patients with ALK fusion-positive NSCLC. ALTA-1LThe results of the trial showed that patients in the Brigatinib/Brigatinib treatment group showed significant advantages in progression-free survival (PFS). The median progression-free survival was 24 months in the brigatinib group and 11 months in the crizotinib group. In addition, overall survival (OS) in the brigatinib/brigatinib group also showed a positive trend, but statistical significance has not yet been reached.

2.Second-line treatment efficacy: For NSCLC patients who have received other ALK inhibitor treatments and developed drug resistance, brigatinib/Brigatinib still has certain efficacy. The results of the clinical trial (ALTA) showed that Brigatinib/Brigatinib showed a higher overall response rate and longer progression-free survival in drug-resistant patients. Research data shows that the overall effective rate of Brigatinib/Brigatinib in drug-resistant patients is 67% to 79%, with a median progression-free survival of 9 to 16 months.

3.Therapeutic effect against specific mutations: For some common ALK drug-resistant mutations, such as ALK< span>T790M mutation, Brigatinib/Brigatinib also shows a certain anti-tumor effect. Studies have shown that Brigatinib/Brigatinib has a certain therapeutic effect on patients with ALKT790M mutations. This mutation is relatively common after ALK inhibitor treatment, and the application of brigatinib may provide an alternative treatment option.

5.Control of intracranial metastasis: Brigatinib/Brigatinib has also shown a certain effect in controlling brain metastasis of lung cancer. Clinical trial data show that Brigatinib/Brigatinib can effectively control the progression of intracranial metastasis in ALKfusion-positive NSCLC patients. Intracranial metastasis has an important impact on the prognosis and quality of life of patients. Treatment with brigatinib/brigatinib can improve the control of intracranial metastasis and increase the survival rate of patients.

Overall, Brigatinib/Brigatinib, as an ALK inhibitor, has shown significant anti-tumor effects in the treatment of ALK fusion-positive NSCLC patients. In the first-line treatment, Brigatinib/Brigatinib showed longer progression-free survival than crizotinib. Among drug-resistant patients, Brigatinib/Brigatinib still has a higher overall response rate and longer progression-free survival. In addition, for some common ALK resistance mutations, Brigatinib/Brigatinib also shows certain anti-tumor effects. However, specific efficacy is also affected by individual differences, disease stage, and other factors. Therefore, before using brigatinib/brigatinib, patients should consult a professional physician for a comprehensive evaluation.

Brigatinib/Brigatinib has been launched in China and has been included in medical insurance. Since it has just been approved for marketing, patients may not be able to buy it in domestic pharmacies. If you need to purchase it in China, please consult the local pharmacy. However, the price is quite high, more than 10,000 yuan. Foreign Brigatinib/Brigatinib are mainly generic drugs, mainly Bangladeshi and Laos generic drugs. The price of the international version of the Bangladeshi generic drug Yaopin is about 2000yuan, the specification is 90mg*30 tablets; the price of the Laos version of the generic drug is about 600, and the specification is smaller. And the ingredients of domestic original drugs and foreign generic drugs are basically the same.